Protein kinase C regulates adenosine A2a receptor mRNA expression in SH-SY5Y cells

European Journal of Pharmacology

Volumn 336, Issue 1, 1997, Pages 71-80

  Peterfreund, Robert A ^a   Gies, Elizabeth K ^a   Fink, J Stephen ^b  

^a Neurogenetics Laboratory   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adenosine receptor; cAMP; Phorbol ester; Protein kinase C; SH SY5Y neuroblastoma cell

Indexed keywords

ADENOSINE A2A RECEPTOR; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROBLASTOMA CELL; NORTHERN BLOTTING; PRIORITY JOURNAL;

ADENOSINE; CYCLIC AMP; GENE EXPRESSION REGULATION; HUMANS; NEUROBLASTOMA; PHENETHYLAMINES; PROTEIN KINASE C; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE; TUMOR CELLS, CULTURED;

EID: 0030777614     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01194-1     Document Type: Article

References (41)

1. Abbracchio M.P., Cattabeni F., Clementi F., Sher E. Adenosine receptors linked to adenylate cyclase activity in human neuroblastoma cells: Modulation during differentiation. Neuroscience. 30:1989;819-825.
2. 2A receptors in human cells and their interaction. Biochem. Biophys. Res. Commun. 208:1995;871-878.
3. Altiok N., Balmforth A.J., Fredholm B.B. Adenosine receptor-induced cAMP changes in D384 astrocytoma cells and the effect of bradykinin thereon. Acta Physiol. Scand. 144:1992;53-63.
4. Burns, D.J., Basta, P.V., Holmes, W.D., Ballas, L.M., Rankl, N.B., Barbee, J.L., Bell, R.M., Loomis, C.R., 1992. In: Papa, S., Azzi, A., Tager, J.M. (Eds.), Structure-Function Studies on the Protein Kinase C Family Members, Adenine Nucleotides in Cellular Energy Transfer and Signal Transduction. Birkhauser Verlag, Basel, pp. 207-217.
5. 2A receptor-mediated cAMP elevation in rat pheochromocytoma PC12 cells. Mol. Pharmacol. 44:1993;950-958.
6. Cronstein B.N. Adenosine, an endogenous antiinflammatory agent. J. Appl. Physiol. 76:1994;5-13.
7. Ferry R.C., Unsworth C.D., Artymyshyn R.P., Molinoff P.B. Regulation of mRNA encoding 5-HT2a receptors in P11 cells through a post-transcriptional mechanism requiring activation of protein kinase C. J. Biol. Chem. 269:1994;31850-31857.
8. Feve B.F.P.-R., el Hadri K., Drumare M.F., Strosberg A.D. Long term phorbol ester treatment down-regulates the beta 3-adrenergic receptor in 3T3-F442A adipocytes. J. Biol. Chem. 270:1995;10952-10959.
9. Fink J.S. Neurobiology of basal ganglia receptors. Clin. Neurosci. 1:1993;27-35.
10. Fink J.S., Verhave M., Walton K., Mandel G., Goodman R.H. Cyclic AMP-and phorbol ester-induced transcriptional activation are mediated by the same enhancer element in the human vasoactive intestinal peptide gene. J. Biol. Chem. 266:1991;3882-3887.
11. Fredholm B.B., Abbracchio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., Williams M. Nomenclature and classification of purinoreceptors. Pharmacol. Rev. 46:1994;143-156.
12. Fujimoto J., Gershengorn M.C. Evidence for dual regulation by protein kinases A and C of thryotropin releasing hormone receptor mRNA in GH3 cells. Endocrinol. 129:1991;3430-3432.
13. 3 cells: Evidence that protein kinase-C mediates the TRH effect. Mol. Endocrinol. 5:1991;1527-1532.
14. Furlong T., Pierce K., Selbie L., Shine J. Molecular characterization of a human brain adenosine A2 receptor. Mol. Brain Res. 15:1992;62-66.
15. Gershengorn M.C., Narayanan C.S., Fujimoto J. Phorbol myristate acetate enhances degradation of TRH receptor mRNA in a pituitary cell type-specific manner. Mol. Cell. Neurosci. 5:1994;576-579.
16. Hadcock J.R., Wang H., Malbon C.C. Agonist-induced destabilization of beta adrenergic receptor mRNA. J. Biol. Chem. 264:1989;19928-19933.
17. Hausdorff W.P., Caron M.G., Lefkowitz R.J. Turning off the signal: Desensitization of β-adrenergic receptor function. FASEB J. 4:1990;2881-2889.
18. Hawkins M., Pan W., Stefanovich P., Radulovacki M. Desensitization of adenosine A2 receptors in the striatum of the rat following chronic treatment with diazepam. Neuropharmacology. 27:1988;1131-1140.
19. Hecker, E., 1978. Structure-activity relationships in diterpene esters irritant and cocarcinogenic to mouse skin. In: Slaga, T.J., Sivak, A., Boutwell, R.K. (Eds.), Carcinogenesis. Raven Press, New York, pp. 11-25.
20. Heikkila J., Jalava A., Eriksson K. The selective protein kinase C inhibitor GF109203X inhibits phorbol ester-induced morphological and functional differentiation of SH-SY5Y human neuroblastoma cells. Biochem. Biophys. Res. Commun. 197:1993;1185-1193.
21. Horwitz J. Muscarinic receptor stimulation increases inositol-phospholipid metabolism and inhibits cyclic AMP accumulation in PC-12 cells. J. Neurochem. 53:1989;197-204.
22. Hosoda K., Fitzgerald L.R., Vaidya V.A., Feussner G.K., Fishman P.H., Duman R.S. Regulation of beta 2-adrenergic receptor mRNA and gene transcription in rat C6 glioma cells: Effects of agonist, forskolin, and protein synthesis inhibition. Mol. Pharmacol. 48:1995;206-211.
23. Jacobson K.A., Nikodijevic O., Padgett W.L., Gallo-Rodriguez C., Maillard M., Daly J.W. 8-(3-chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo. FEBS Lett. 323:1993;141-144.
24. Jalava A., Akerman K., Heikkila J. Protein kinase inhibitor, staurosporine, induces a mature neuronal phenotype in SH-SY5Y human neuroblastoma cells in a a-, b-, and z protein kinase C-independent pathway. J. Cell. Physiol. 155:1993;301-312.
25. Jarvis M.F., Schulz R., Hutchison A.J., Do U.H., Sills M.A., Williams M. [3H]CGS21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in the rat brain. J. Pharmacol. Exp. Ther. 251:1989;888-893.
26. Kiley S.C., Jaken S. Protein kinase C: Interactions and consequences. Trends Cell Biol. 4:1994;223-228.
27. Leli U., Cataldo A., Shea T.B., Nixon R.A., Hauser G. Distinct mechanisms of differentiation of SH-SY5Y neuroblastoma cells by protein kinase C activators and inhibitors. J. Neurochem. 58:1992;1191-1198.
28. Linden J., Taylor H.E., Robeva A.S., Tucker A.L., Stehle J.H., Rivkees S.A., Fink J.S., Reppert S.M. Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution. Mol. Pharmacol. 44:1993;524-532.
29. 2A receptor (ADORA2) to chromosome 22. Genomics. 20:1994;332-333.
30. Mullane, K.M., Williams, M., 1990. In: Williams, M. (Ed.), Adenosine and Cardiovascular Function, Adenosine and Adenosine Receptors. Humana Press, Clifton, NJ, pp. 289-334.
31. Olah M.E., Stiles G.L. Adenosine receptor subtypes: Characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol. 35:1995;581-606.
32. 2A receptor: Delineation of multiple processes. Mol. Pharmacol. 45:1994;1082-1094.
33. 2A receptor gene. J. Neurochem. 66:1996;362-368.
34. Porter N.M., Radulovacki M., Green R.D. Desensitization of adenosine and dopamine receptors in rat brain after treatment with adenosine analogs. J. Pharmacol. Exp. Ther. 244:1988;218-225.
35. Ramkumar V., Olah M.E., Jacobsen K.A., Stiles G.L. Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1MF-2 cells. Mol. Pharmacol. 40:1991;639-647.
36. Reeve H.L., Vaughan P.F.T., Peers C. Enhancement of Ca2++ channel currents in human neuroblastoma (SH-SY5Y) cells by phorbol esters with and without activation of protein kinase C. Pflug. Arch. Eur. J. Physiol. 429:1995;729-737.
37. 2B receptor. Mol. Endocrinol. 6:1992;1598-1604.
38. 2A receptor mRNA expression by agonists and forskolin in PC12 cells. NeuroReport. 5:1994;1317-1320.
39. Toullec D., Pianetti P., Coste H., Bellevergue P., Grand-Perret T., Ajakane M., Baudet V., Boissin P., Boursier E., Loriolle F., Duhamel L., Charon D., Kirilovsky J. The bisindolylmaleimide GF109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266:1991;15771-15781.
40. Wang H., Segaloff D.L., Ascoli M. Epidermal growth factor and phorbol esters reduce the levels of the cognate mRNA for the LH/CG receptor. Endocrinol. 128:1991;2651-2653.
41. Wang H., Segaloff D.L., Ascoli M. Lutropin/choriogonadotropin down-regulates its receptor by both receptor-mediated endocytosis and a cAMP-dependent reduction in receptor mRNA. J. Biol. Chem. 266:1991;780-785.